Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) comprises fat-accumulating conditions within hepatocytes that can cause severe liver damage and metabolic comorbidities. Studies suggest that mitochondrial dysfunction contributes to its development and progression and that the hepatic lipidome changes extensively in obesity and in NAFLD. To gain insight into the relationship between lipid metabolism and disease progression through different stages of NAFLD, we performed lipidomic analysis of plasma and liver biopsy samples from obese patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) and from those without NAFLD. Congruent with earlier studies, hepatic lipid levels overall increased with NAFLD. Lipid species that differed with NAFLD severity were related to mitochondrial dysfunction; specifically, hepatic cardiolipin and ubiquinone accumulated in NAFL, and levels of acylcarnitine increased with NASH. We propose that increased levels of cardiolipin and ubiquinone may help to preserve mitochondrial function in early NAFLD, but that mitochondrial function eventually fails with progression to NASH, leading to increased acylcarnitine. We also found a negative association between hepatic odd-chain phosphatidylcholine and NAFLD, which may result from mitochondrial dysfunction-related impairment of branched-chain amino acid catabolism. Overall, these data suggest a close link between accumulation of specific hepatic lipid species, mitochondrial dysfunction, and the progression of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ceramides are among the most studied lipids because of their lipotoxic activity in several organs and have been reported to be increased in the plasma of patients with MASLD.94,[99], [100], [101], [102],[107], [108], [109],115”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [99]
In the citing paper
“Peng et al.99 showed that TAGs, DAGs, ceramides, PE, lysophosphatidylethanolamine and cholesterol esters were significantly increased, and PC and LPC significantly reduced, in MASH vs. controls (Table 1).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Branched-chain amino acids in metabolic signalling and insulin resistance
Lynch, C. J., & Adams, S. H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.171 · Cited by 1,461
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 1×
“In the current study, we found increased hepatic levels of TG, DG, CE, and free cholesterol in individuals with NAFLD, which is in congruence with earlier studies (19, 20).”
ResultKoliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
Cardiolipin Stabilizes Respiratory Chain Supercomplexes
Pfeiffer, K., Gohil, V., Stuart, R. A., Hunte, C., Brandt, U., Greenberg, M. L., & Schägger, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308366200 · Cited by 843 · cited 1×
“Cardiolipin is also important for mitochondrial biogenesis and the assembly of respiratory enzyme supercomplexes (25).”
BackgroundMitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753 · cited 1×
“Mitochondrial dysfunction has been suggested to play a pivotal role in the pathogenesis of NAFLD (13, 14).”
BackgroundDefective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.
Pérez-Carreras, M., Del Hoyo, P., Martín, M. A., Rubio, J. C., Martín, A., Castellano, G., Colina, F., Arenas, J., & Solis-Herruzo, J. A. (2003) · Hepatology · doi:10.1002/hep.1840380426 · Cited by 734
ARAYA, J., RODRIGO, R., VIDELA, L. A., THIELEMANN, L., ORELLANA, M., PETTINELLI, P., & PONIACHIK, J. (2004) · Clinical Science · doi:10.1042/cs20030326 · Cited by 700
Cited by
The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
Self-citationHow does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 432
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
Hodson, L., & Gunn, P. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0256-9 · Cited by 309
Metabolic and Signaling Roles of Ketone Bodies in Health and Disease
Puchalska, P., & Crawford, P. A. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-111120-111518 · Cited by 282
Emami, N. K., Jung, U., Voy, B., & Dridi, S. (2020) · Antioxidants · doi:10.3390/antiox10010035 · Cited by 247
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Meex, R. C. R., Blaak, E. E., & van Loon, L. J. C. (2019) · Obesity Reviews · doi:10.1111/obr.12862 · Cited by 211
“The liver on its turn also secretes a wide range of lipids, including high levels of triacylglycerols via the secretion of very‐low‐density lipoproteins.(73) These lipids can accumulate in skeletal muscle and contribute to the development of insulin resistance (see following paragraph).”
BackgroundSelf-citationOxidative stress: The nexus of obesity and cognitive dysfunction in diabetes
Li, H., Ren, J. L., Li, Y., Wu, Q., & Wei, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134025 · Cited by 200
“Significantly elevated levels of acylcarnitine in patients with nonalcoholic fatty liver mark mitochondrial dysfunction and impaired fatty acid oxidation (65).”
BackgroundMitochondrial membrane lipids in the regulation of bioenergetic flux
Decker, S. T., & Funai, K. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.024 · Cited by 166
“136,138 Exogenous CL, but not peroxidized CL or other phospholipids, restored some of the OXPHOS defects associated with MASLD.”
BackgroundLipidomics in non-alcoholic fatty liver disease
Kartsoli, S., Kostara, C. E., Tsimihodimos, V., Bairaktari, E. T., & Christodoulou, D. K. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.436 · Cited by 163
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“A recent study conducted by Mucinski et al. 57 supported the idea that ceramides, DAGs, and TAGs are packaged together in the liver in VLDL and secreted together into the bloodstream.”
InfluentialNonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 153
Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases
Mooli, R. G. R., Mukhi, D., & Ramakrishnan, S. K. (2022) · Comprehensive physiology · doi:10.1002/cphy.c200021 · Cited by 151
Zhang, J., Zhang, W., Yang, L. H., Zhao, W., Liu, Z., Wang, E., & Wang, J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154589 · Cited by 140
An integrative systems genetic analysis of mammalian lipid metabolism
Parker, B. L., Calkin, A. C., Seldin, M. M., Keating, M. F., Tarling, E. J., Yang, P., Moody, S. C., Liu, Y., Zerenturk, E. J., Needham, E. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0984-y · Cited by 137
Self-citationYu, L., Hong, W., Lu, S., Li, Y., Guan, Y., Weng, X., & Feng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.780496 · Cited by 149
“Cardiolipin is effective in stimulating NLRP3 inflammasome through a ROS-independent signaling pathway, and its deficiency is protected against hepatic steatosis (Peng et al., 2018).”
BackgroundLongo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.11.007 · Cited by 129
Longo, M., Meroni, M., Paolini, E., Macchi, C., & Dongiovanni, P. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154708 · Cited by 123
Enooku, K., Nakagawa, H., Fujiwara, N., Kondo, M., Minami, T., Hoshida, Y., Shibahara, J., Tateishi, R., & Koike, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-47216-2 · Cited by 119
Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications
Thyfault, J. P., & Rector, R. S. (2020) · Diabetes · doi:10.2337/dbi18-0043 · Cited by 109
“Current evidence in rodents and humans using both in vivo and in vitro tools shows that obesity and high-fat diets, factors that drive steatosis, lead to compensatory increases in measures of mitochondrial oxidative capacity including tricarboxylic acid cycle flux, FAO, and mitochondrial respiratory capacity (9–11), w…”
BackgroundInfluentialMitochondrial oxidative function in NAFLD: Friend or foe?
Shum, M., Ngo, J., Shirihai, O. S., & Liesa, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101134 · Cited by 122
“Supporting this view, the increase in acylcarnitine intermediates due to incomplete fatty acid oxidation is associated with NAFLD [45,46] and these intermediates were shown to contribute to insulin resistance in muscle [47].”
BackgroundMeex, R. C. R., & Blaak, E. E. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900942 · Cited by 125
Self-citationAnti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes
Kuryłowicz, A., & Koźniewski, K. (2020) · Molecules · doi:10.3390/molecules25092224 · Cited by 114
“In turn, celecoxib (selective COX-2 inhibitor) reversed NASH in rats with diabetes induced by a high-fat and sucrose (HF-HS) diet that was reflected by a reduced inflammatory infiltration and lower activity of pro-inflammatory pathways in the livers [161].”
BackgroundInfluentialCavaliere, G., Cimmino, F., Trinchese, G., Catapano, A., Petrella, L., D’Angelo, M., Lucchin, L., & Mollica, M. P. (2023) · Antioxidants · doi:10.3390/antiox12061172 · Cited by 118
“Indeed, individuals with hepatic steatosis had ∼5-fold higher mitochondrial respiration, and an increased mitochondrial fatty acid oxidation, considered a protective mechanism against NAFLD progression [82].”
BackgroundReign in the membrane: How common lipids govern mitochondrial function
Funai, K., Summers, S. A., & Rutter, J. P. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.006 · Cited by 104
van den Berg, E. H., Flores-Guerrero, J. L., Gruppen, E. G., de Borst, M. H., Wolak, J. E., Connelly, M. A., Bakker, S. J. L., & Dullaart, R. P. F. (2019) · Nutrients · doi:10.3390/nu11030705 · Cited by 104
“Accumulating evidence points to a key role of mitochondrial dysfunction in the pathophysiology and progression of NAFLD, possibly caused b increased mitochondrial β-oxidation of fatty acids in insulin-resistant states [28,29] and by impaired adaptation of hepatic mitochondrial function in NAFLD [30].”
BackgroundTripathi, M., Yen, P. M., & Singh, B. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051645 · Cited by 100
Oxidative Stress in Non-Alcoholic Fatty Liver Disease
Smirne, C., Croce, E., Benedetto, D. D., Cantaluppi, V., Comi, C., Sainaghi, P. P., Minisini, R., Grossini, E., & Pirisi, M. (2022) · Livers · doi:10.3390/livers2010003 · Cited by 111
Mitochondrial Dysfunction in the Transition from NASH to HCC
Léveillé, M., & Estall, J. L. (2019) · Metabolites · doi:10.3390/metabo9100233 · Cited by 100
Shi, S., Wang, X., van der Laan, L. J. W., Pan, Q., & Verstegen, M. M. A. (2021) · Transplantation · doi:10.1097/tp.0000000000003691 · Cited by 96
Jing, J., Zeng, H., Shao, Q., Tang, J., Wang, L., Jia, G., Liu, G., Chen, X., Tian, G., Cai, J., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102912 · Cited by 79
“Mitochondrion is the ultimate metabolic center for lipid and glucose, mitochondrial dysfunction generally inhibits the hepatic lipid catabolism and causes lipid accumulation [13].”
BackgroundPlasma acylcarnitine levels increase with healthy aging
Jarrell, Z. R., Smith, M. R., Hu, X. Y., Orr, M. L., Liu, K., Quyyumi, A. A., Jones, D. P., & Go, Y. (2020) · Aging · doi:10.18632/aging.103462 · Cited by 82
“Acylcarnitines are also transported into plasma [25], and as a consequence, plasma acylcarnitine levels can serve as an indicator of mitochondrial function [36].”
BackgroundAssociation of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer
Rajesh, Y., & Sarkar, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042163 · Cited by 82
Zhang, R., Chu, K., Zhao, N., Wu, J., Ma, L., Zhu, C., Chen, X., Wei, G., & Liao, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01693 · Cited by 71
“…mitochondrial dysfunction, which have been observed prior to the natural history of NAFLD in obese, Otsuka Long-Evans Tokushima Fatty (OLETF) rat (Rector et al., 2010). mtDNA that encodes mitochondrial respiratory chain (MRC) polypeptides, presented in several copies within mitochondrial matrix…”
BackgroundSpremović-Radjenović, S., Pupovac, M., Andjić, M., Bila, J. S., Sreckovic, S. D., Gudović, A., Dragaš, B., & Radunović, N. V. (2022) · Biomedicines · doi:10.3390/biomedicines10010131 · Cited by 78
Is copper a new target to counteract the progression of chronic diseases?
Balsano, C., Porcu, C., & Sideri, S. (2018) · Metallomics · doi:10.1039/c8mt00219c · Cited by 69
NLRP3 inflammasome in hepatic diseases: A pharmacological target
Ramos‐Tovar, E., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115861 · Cited by 75
Xia, H., Zhu, X., Zhang, X., Jiang, H., Li, B., Wang, Z., Li, D., & Jin, Y. J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109287 · Cited by 68
Drug-Induced Mitochondrial Toxicity in the Geriatric Population: Challenges and Future Directions
Will, Y., Shields, J. E., & Wallace, K. B. (2019) · Biology · doi:10.3390/biology8020032 · Cited by 67
Gutiérrez‐Cuevas, J., Lucano‐Landeros, S., López-Cifuentes, D., Santos, A., & Armendáriz‐Borunda, J. (2022) · Cancers · doi:10.3390/cancers15010023 · Cited by 68
Shannon, C. E., Ragavan, M., Palavicini, J. P., Fourcaudot, M. J., Bakewell, T. M., Valdez, I., Ayala, I., Jin, E. S., Madesh, M., Han, X., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101154 · Cited by 68
“In agreement with evidence from human NASH patients [62,82], total acylcarnitine content was elevated in OB-CON livers, reflecting an imbalance between CPTI-mediated acylcarnitine production and their disposal via b-oxidation.”
BackgroundSimões, I. C. M., Amorim, R., Teixeira, J., Karkucińska‐Więckowska, A., Carvalho, A., Pereira, S. P., Simões, R. F., Szymańska, S., Dąbrowski, M., Janikiewicz, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136848 · Cited by 66
Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use
Spooner, M. H., & Jump, D. Β. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061021-030223 · Cited by 64
“Cardiolipin is interesting in the context of metabolic disease because the acyl chains in cardiolipin are predominantly C 18–22 PUFAs, both ω 3 and ω 6, and diet significantly affects cardiolipin acyl chain composition and mitochondrial function (23, 78, 100, 103, 104, 106, 125, 126).”
Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
Longo, M., Paolini, E., Meroni, M., & Dongiovanni, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084173 · Cited by 65
“Finally, the lipidomic analysis of NASH patients revealed higher hepatic levels of dihydroceramide and dihexosylceramide species that were correlated to defects of mitophagy, oxidative stress and inflammation [89].”
BackgroundThe role of hepatic lipid composition in obesity‐related metabolic disease
Willis, S. A., Bawden, S., Malaikah, S., Sargeant, J. A., Stensel, D. J., Aithal, G. P., & King, J. A. (2021) · Liver International · doi:10.1111/liv.15059 · Cited by 69
Tian, Y., Jellinek, M. J., Mehta, K., Seok, S. M., Kuo, S. H., Lu, W., Shi, R., Lee, R. G., Lau, G. W., Kemper, J. K., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000375 · Cited by 65
“[ 28 ] Further analysis of RNA sequencing data showed that a majority of mitochondria-encoded genes were significantly downregulated in LKO livers (Supplemental Figure S4A, http://links.lww.com/HEP/ F18).”
MethodSerum levels of copper and zinc in diabetic retinopathy: Potential new therapeutic targets (Review)
Dascălu, A. M., Anghelache, A., Stana, D., Costea, A. C., Nicolae, V. A., Tănăsescu, D., Costea, D. O., Tribus, L. C., Zgura, A. F., Şerban, D., et al. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11253 · Cited by 60
“An accumulation of Cu in the liver may be due to decreased insulin levels (59).”
BackgroundmiR ‐21‐5p promotes NASH ‐related hepatocarcinogenesis
Rodrigues, P. M., Afonso, M. B., Simão, A. L., Islam, T., Gaspar, M. M., O’Rourke, C. J., Lewińska, M., Andersen, J. B., Arretxe, E., Alonso, C., et al. (2023) · Liver International · doi:10.1111/liv.15682 · Cited by 52
Durand, M., Coué, M., Croyal, M., Moyon, T., Tesse, A., Atger, F., Ouguerram, K., & Jacobi, D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9986299 · Cited by 55
Acetaminophen aggravates fat accumulation in NAFLD by inhibiting autophagy via the AMPK/mTOR pathway
Shi, C., Xue, W., Han, B., Yang, F., Yin, Y., & Hu, C. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.005 · Cited by 50
Ramanathan, R., Patwa, S. A., Ali, A. H., & Ibdah, J. A. (2023) · Cells · doi:10.3390/cells12242806 · Cited by 51
“Published reports from our group and others document that hepatic mitochondrial dysfunction plays a key role in the progression of MASLD [10–14].”
ResultYin, X., Liu, Z., & Wang, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155005 · Cited by 50
Song, K., Zhang, Y., Ga, Q., Bai, Z., & Ge, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117633 · Cited by 44
Han, H., Li, X., Guo, Y., Zheng, M., Xue, T., & Wang, L. (2021) · Food & Function · doi:10.1039/d0fo02623a · Cited by 50
de Oliveira, D. T., Chaves‐Filho, A. B., Yoshinaga, M. Y., de Paiva, N. C. N., Carneiro, C. M., Miyamoto, S., Festuccia, W. T., & Guerra‐Sá, R. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108519 · Cited by 43
Ren, F., Chen, Q., Chen, M., Chen, H., Zhou, Y., Zhang, H., & Chen, W. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104496 · Cited by 40
Draijer, L. G., Froon-Torenstra, D., van Weeghel, M., Vaz, F. M., Bohte, A. E., Holleboom, A. G., Benninga, M. A., & Koot, B. G. P. (2020) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002875 · Cited by 43
“This finding is consistent with previous studies that evaluated steatotic liver tissue (18,46) and plasma samples of patients with NAFLD (19,31,34).”
Xue, L., Liu, K., Yan, C., Dun, J., Xu, Y., Wu, L., Yang, H., Liu, H., Xie, L., Wang, G., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.04.009 · Cited by 41
Insights into genetic variants associated with NASH-fibrosis from metabolite profiling
Mann, J. P., Pietzner, M., Wittemans, L. B., Rolfe, E. D. L., Kerrison, N. D., Imamura, F., Forouhi, N. G., Fauman, E., Allison, M. E., Griffin, J. L., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa162 · Cited by 38
Pham, A. C., Peng, K., Salim, M., Ramirez, G., Hawley, A. M., Clulow, A. J., & Boyd, B. J. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00131 · Cited by 37
Self-citationHigh-Resolution Metabolomic Assessment of Pesticide Exposure in Central Valley, California
Yan, Q. J., Paul, K. C., Walker, D. I., Furlong, M., Rosario, I. D., Yu, Y., Zhang, K., Cockburn, M., Jones, D. P., & Ritz, B. R. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00523 · Cited by 37
Mechanism of Obesity-Related Lipotoxicity and Clinical Perspective
Engin, A. B. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_5 · Cited by 43
Metabolomics at the cutting edge of risk prediction of MASLD
Tan, E. Y., Muthiah, M. D., & Sanyal, A. J. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101853 · Cited by 50
“24 Plasmalogens are a group of vinyl ether phospholipids with antioxidant properties.”
Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease
Hendrikx, T., & Binder, C. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607011 · Cited by 37
Castañé, H., Baiges‐Gayà, G., Hernández‐Aguilera, A., Rodríguez‐Tomàs, E., Fernández‐Arroyo, S., Herrero, P., Delpino-Rius, A., Canela-Canela, N., Menéndez, J. A., Camps, J., et al. (2021) · Biomolecules · doi:10.3390/biom11030473 · Cited by 36
“Mitochondrial lipids and the communication with lipid biosynthesis in endoplasmic reticulum may cause liver disease via defective mitochondrial function, which is highly dependent on a regulated supply of phospholipids and proteins [86,100,101,111].”
BackgroundCiaula, A. D., Calamita, G., Shanmugam, H., Khalil, M., Bonfrate, L., Wang, D. Q. ‐., Baffy, G., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147702 · Cited by 36
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“In the liver, surplus FFAs initially stimulate mitochondrial activity but chronic FFA overload damages mitochondria, resulting in impaired fatty acid oxidation (FAO) and accumulation of acylcarnitines 91,92 .”
Mietus‐Snyder, M., Perak, A. M., Cheng, S. C., Hayman, L. L., Haynes, N., Meikle, P. J., Shah, S. H., & Suglia, S. F. (2023) · Circulation · doi:10.1161/cir.0000000000001185 · Cited by 35
Self-citationThe Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases
Wang, Z., Chen, N., Li, Z., Xu, G., Zhan, X., Tang, J., Xiao, X., & Bai, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.717610 · Cited by 35
Martínez-Sena, T., Moro, E., Moreno‐Torres, M., Quintás‐Cardama, A., Hengstler, J. G., & Castell, J. V. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03474-8 · Cited by 33
Genetic regulation of liver lipids in a mouse model of insulin resistance and hepatic steatosis
Norheim, F., Krishnan, K. C., Bjellaas, T., Vergnes, L., Pan, C., Parks, B. W., Meng, Y., Lang, J., Ward, J. A., Reue, K., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209684 · Cited by 32
“These analyses have highlighted the complexity of lipid species and generated correlative links to several chronic diseases (Gorden et al, 2015; Luukkonen et al, 2016; Peng et al, 2018).”
BackgroundRole of hepatic lipid species in the progression of nonalcoholic fatty liver disease
Deng, K., Huang, X., Lei, F., Zhang, X., Zhang, P., She, Z., Cai, J., Ji, Y., & Li, H. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00123.2022 · Cited by 32
Yu, J.-Y., Cao, N., Rau, C. D., Lee, R.-P., Yang, J., Flach, R. J. R., Petersen, L., Zhu, C., Pak, Y.-L., Miller, R., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01076-9 · Cited by 32
Grattagliano, I., Ciaula, A. D., Baj, J., Molina‐Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1433-4_12 · Cited by 30
Herrera-Marcos, L. V., Martínez‐Beamonte, R., Arnal, C., Barranquero, C., Puente‐Lanzarote, J. J., Herrero‐Continente, T., Lou-Bonafonte, J. M., Gonzalo, G., Mocciaro, G., Jenkins, B., et al. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109207 · Cited by 32
Fu, J., Hu, F., Ma, T., Zhao, W., Tian, H., Zhang, Y., Hu, M., Zhou, J., Zhang, Y., Jian, C., et al. (2021) · Hepatology · doi:10.1002/hep.32126 · Cited by 29
Flóres, Y. N., Amoon, A. T., Su, B., Velázquez‐Cruz, R., Ramírez‐Palacios, P., Salmerón, J., Rivera‐Paredez, B., Sinsheimer, J. S., Lusis, A. J., Huertas‐Vázquez, A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01526-5 · Cited by 32
“For example, lipidomics analyses were conducted on plasma from Mexican American participants in the San Antonio Family Heart Study to investigate links with cardiovascular disease [65] and hypertension [66], but they did not examine the association between NAFLD and specific lipids.”
MethodResultVouilloz, A., Bourgeois, T., Diedisheim, M., Pilot, T., Jalil, A., Guern, N. L., Bergas, V., Rohmer, N., Castelli, F. A., Leleu, D., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156051 · Cited by 31
“Indeed, it is well established that changes in mitochondrial function and complex activity are inherent to the progression toward MASH [47,48].”
9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes
Moreira, A. R. S., Rüschenbaum, S., Schefczyk, S., Hendgen-Cotta, U. B., Rassaf, T., Broering, R., Hardtke‐Wolenski, M., & Buitrago‐Molina, L. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218279 · Cited by 25
“The NAFLD disease spectrum includes nonalcoholic fatty liver (NAFL) and the advanced form of nonalcoholic steatohepatitis with inflammation and mitochondrial dysfunction (NASH) [2]; both of these conditions are characterized by the accumulation of fat in more than 5% of hepatocytes [3,4].”
BackgroundDefining NASH from a Multi-Omics Systems Biology Perspective
Niu, L., Sulek, K., Vasilopoulou, C. G., Santos, A., Albrechtsen, N. J. W., Rasmussen, S., Meier, F., & Mann, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204673 · Cited by 24
The involvement of the mitochondrial membrane in drug delivery
Huang, Y., Ji, W., Zhang, J., Huang, Z. H., Ding, A., Bai, H., Peng, B., Huang, K., Du, W., Zhao, T., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.027 · Cited by 26
Bochkova, Z. V., Baizhumanov, A. A., Yusipovich, A. I., Morozova, K. I., Nikelshparg, E. I., Fedotova, A. A., Tiaglik, A. B., Yu, X., Brazhe, A., Maksimov, G. V., et al. (2025) · Biophysical Reviews · doi:10.1007/s12551-025-01270-5 · Cited by 26
“In rats, elevated levels of peroxidized CL have been observed in metabolic dysfunction-associated steatotic liver disease (MASLD) (Peng et al. 2018).”
Aqeel, A., Akram, A., Ali, M., Iqbal, M., Aslam, M., Rukhma, & Shah, F. I. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112129 · Cited by 24
Anari, M., & Montgomery, M. K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115621 · Cited by 24
Niu, Z., Fu, M., Li, Y., Ren, H., Zhang, X., & Li, Y. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153840 · Cited by 23
Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2023) · Metabolites · doi:10.3390/metabo13060757 · Cited by 24
The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression
Caputo, V., Tarantino, G., Santini, S. J., Fracassi, G., & Balsano, C. (2023) · Nutrients · doi:10.3390/nu15224757 · Cited by 24
“Thus, as mentioned above, the loss of mitochondrial function together with the oxidative stress may be considered typical hallmarks of NAFLD and markers of progression [17,18].”
BackgroundZhang, L., Shi, H.-H., Wang, C., Wang, Y.-M., Wei, Z., Xue, C., Mao, X., & Zhang, T. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07538 · Cited by 23
Liver saturated fat content associates with hepatic DNA methylation in obese individuals
Sehgal, R., Perfilyev, A., Männistö, V., Ågren, J., Nilsson, E., Käkelä, P., Ling, C., de Mello, V. D., & Pihlajamäki, J. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01431-x · Cited by 21
“An excessive accumulation of SFAs in liver TG in individuals with non-alcoholic fatty liver or NASH compared to the normal liver has been recently reported [10].”
BackgroundMitochondrial DNA methylation in metabolic associated fatty liver disease
Mposhi, A., Cortés-Mancera, F., Heegsma, J., de Meijer, V. E., van de Sluis, B., Sydor, S., Bechmann, L. P., Theys, C., Rijk, P. D., Pooter, T. D., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.964337 · Cited by 22
“org methylation was higher, and associated with lower ND6 expression in (1) liver samples of MeSH patients compared to samples obtained from SS patients (8), and (2) leucocytes of Type II diabetes patients (22).”
BackgroundResultHan, H., Guo, Y., Li, X., Shi, D., Xue, T., Wang, L., Li, Y., & Zheng, M. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8294141 · Cited by 25
“Impaired mitochondrial FA β-oxidation may result in fat accumulation in the liver and implicate in the pathogenesis of NAFLD [11].”
BackgroundShi, Y., Pizzini, J. D., Wang, H., Das, F., Azees, P. A. A., Choudhury, G. G., Barnes, J. L., Zang, M., Weintraub, S. T., Yeh, C., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00651.2020 · Cited by 26
Cardiolipin Alterations during Obesity: Exploring Therapeutic Opportunities
Prola, A., & Pilot‐Storck, F. (2022) · Biology · doi:10.3390/biology11111638 · Cited by 23
“Liver biopsies from human patients showed a global increase in cardiolipin content both in NAFLD and the more severe non-alcoholic steatohepatitis (NASH) [6].”
BackgroundInfluentialLu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H. L., McCain, M. V., Chambers, E. S., Ward, C. E., Sartika, D., et al. (2022) · Liver Cancer · doi:10.1159/000525911 · Cited by 22
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice
Tan, R., Li, J., Liu, L., Wu, Q., Fan, L., Ma, N., Yu, C., Lu, H., Zhang, X., Chen, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415931 · Cited by 19
Fructose aggravates copper-deficiency-induced non-alcoholic fatty liver disease
Jiang, X. M., Hu, R., Huang, Y., Xu, Y., Zheng, Z., Shi, Y., Miao, J., & Liu, Y. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109402 · Cited by 19
Postprandial Dysmetabolism and Its Medical Implications
Sasso, E., Batičić, L., & Tokmadžić, V. S. (2023) · Life · doi:10.3390/life13122317 · Cited by 22
“This is the result of impaired lipid metabolism, in which lipid accumulation leads to mitochondrial dysfunction and subsequently triggers non-alcoholic fatty steatohepatitis (NASH) [49,50].”
BackgroundDisturbed intramitochondrial phosphatidic acid transport impairs cellular stress signaling
Eiyama, A., Aaltonen, M. J., Nolte, H., Tatsuta, T., & Langer, T. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100335 · Cited by 19
Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
Sessa, A. D., Riccio, S., Pirozzi, E., Verde, M., Passaro, A. P., Umano, G. R., Guarino, S., del Giudice, E. M., & Marzuillo, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i25.3815 · Cited by 20
Liu, A., Duan, G., Yang, L., Hu, Y., Zhou, H., & Wang, H. (2025) · Antioxidants · doi:10.3390/antiox14070762 · Cited by 20
“Accumulation of acylcarnitines has been confirmed to be closely associated with mitochondrial dysfunction in mammalian non-alcoholic fatty liver disease (NAFLD) [75,76].”
Metadata
- Authors
- Peng, K.-Y., Watt, M. J., Rensen, S., Greve, J. W., Huynh, K., Jayawardana, K. S., Meikle, P. J., & Meex, R. C. R.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- The University of Melbourne (AU)
- Maastricht University Medical Centre (NL)
- Zuyderland Medisch Centrum (NL)
- Corresponding author
- Meikle, Peter J.
- Meex, Ruth C.R.
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 59
- Issue
- 10
- Pages
- 1977-1986
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC6168306
- OpenAlex
- W2884907724
- Cited by
- 220
- References
- 57
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 33 · 2023: 39 · 2022: 25 · 2021: 43 · 2020: 27 · 2019: 13 · 2018: 2
- FWCI
- 16.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 708 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- National Health and Medical Research Council (APP1061278, APP1077703, APP1042095)
- University of Melbourne
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, mitochondrial dysfunction, hepatic lipidome, cardiolipin, coenzyme Q10, acylcarnitines, branched-chain amino acid catabolism, disease progression, obesity, plasma lipidomics, liver biopsy
- MeSH terms
- Adult, Female, Humans, Liver, Male, Middle Aged, Mitochondria, Cohort Studies, Disease Progression, Lipid Metabolism, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.